Overview

Rhabdomyosarcoma and Malignant Soft Tissue Tumours of Childhood

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Objective of the study objectives was to explore survival advantage for an intensified chemotherapy strategy in a randomised trial. IVA (ifosfamide, vincristine, actinomycin D) or a 6 drug combination (IVA + carboplatin, epirubicin, etoposide) both delivered over 27 weeks. Cumulative dose / m2 = ifosfamide 54g (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug). Delivery of radiotherapy was determined according to site and / or response to chemotherapy ± surgery. The study was powered to detect 10% difference in 3 year OS.
Phase:
Phase 3
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Treatments:
Carboplatin
Epirubicin
Etoposide
Ifosfamide
Vincristine